Currently this is achieved using antibodies targeting receptors PD-1 and CTLA-4 present on T cells, and their respective ligands PD-L1 and CD80 or CD86, expressed on tumor and antigen presenting cells (APCs). The gene discussed is CD274; the disease is neoplasm.